Unlock instant, AI-driven research and patent intelligence for your innovation.

Medicine composition for treating hyperlipemia and coronary disease and preparation method thereof

A composition and technology for coronary heart disease, applied in the directions of drug combination, pharmaceutical formulation, drug delivery, etc., can solve the problems of limited clinical application, slow effect, elevated blood lipids, etc.

Active Publication Date: 2006-09-27
CHONGQING TAIJI INDAL GROUP
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are existing lipid-lowering medicines, or because of the slow effect, or because of the re-elevation of blood lipids after drug withdrawal, the clinical application has been greatly limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0032] Experimental Example 1: Anti-myocardial ischemia test of granules of the present invention

[0033] Test product: finished granules of the present invention Specifications: 27.3g crude drug / 3.2g powder / bag; dosage and administration: Clinically, adults (60kg body weight) take 1 bag each time, 3 times a day, that is, the daily dosage for adults It is: (1 bag / time×3 times / day×27.3g crude drug / bag)÷60kg body weight=1.365g crude drug / kg body weight; 30 days is a course of treatment. The following are calculated according to the original drug, see Table 1. Positive control drug: Di'ao Xinxuekang Capsules, produced by Chengdu Di'ao Pharmaceutical Group Co., Ltd. Batch number 00020501; specification: 100mg×20 capsules. Before use, distilled water was used to make the required concentration of liquid medicine for experimentation, and the following calculations were made according to this, as shown in Table 1. Modeling drug: vasopressin, produced by Shanghai Biochemical Pharm...

experiment example 2

[0039] Experimental example 2: the influence of granule of the present invention on rabbit plasma fibrin degradation product (FDP)

[0040] Granules of the present invention, urokinase for injection, are mixed with required concentration medicinal liquid with 0.996 sodium chloride injection during the test for subsequent use (see Table 3).

[0041]

group

Test substance

drug concentration

(g / ml)

Dosing volume

(ml / kg)

Dosage

(g / kg)

Days of administration

(sky)

medication

way

control group

urokinase group

Granule high dose group of the present invention

The middle dose group of granules of the present invention

Granules of the present invention low dose group

distilled water

Urokinase for Injection

Granules of the present invention

Granules of the present invention

Granules of the present invention

--

1000U / ml

18.2

...

experiment example 3

[0047] Experimental Example 3: Determination of Rabbit Plasma Euglobulin Time (ELT)

[0048] 48 Japanese big-eared white rabbits were randomly divided into 6 groups, 8 rabbits in each group, half male and half male. According to the drugs and doses listed in Table 5, they were administered from the marginal ear vein once a day for 7 consecutive days. 30 minutes after the last administration of animals in each group, blood was taken from the ear vein, anticoagulated with 3.8% sodium citrate (1:9 ratio of anticoagulant and blood), and immediately centrifuged at 3000rpm / min for 10min to separate platelet-poor plasma (PPP) . Calcium addition method is used to measure ETL, the method is as follows: take a centrifuge tube with conical bottom, add 7.5ml of distilled water, add 0.12ml of 0.17mol / L acetic acid, make the pH about 4.5. Place in ice water bath. Add 0.5ml of the above PPP, mix well, continue to put in ice bath for 10min, and centrifuge (2500×g, 5min). Pour off the supe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses medicine composition for treating hyperlipemia and coronary heart disease and its preparation process and quality control method. The medicine composition consists of Chuanxiong rhizome 100-400 weight portions, astragalus root 400-800 weight portions, red peony root 200-500 weight portions, peach kernel 100-300 weight portions, safflower 200-500 weight portions, green tangerine orange peel 100-300 weight portions, angelica 200-500 weight portions, atractylodes rhizome 200-500 weight portions, algae 100-400 weight portions, achyranthes root 100-300 weight portions, bitter orange100-300 weight portions, and balloonflower root 100-300 weight portions. The medicine composition is used for treating hyperlipemia and coronary heart disease.

Description

Field of invention: [0001] The invention relates to a pharmaceutical composition, a preparation method and a quality control method thereof, in particular to a pharmaceutical composition for treating hyperlipidemia and coronary heart disease, a preparation method and a quality control method thereof. Background technique: [0002] The World Health Organization determined that "10% of the elderly population over 65 years old is an aging society", so many countries such as Japan, South Korea, the United States, Switzerland, etc. have entered the aging society. According to the prediction of domestic medical experts, by 2025 our country The elderly over 65 years old will account for 15% of the total population, becoming the country with the largest number of elderly people in the world. With the increase of the elderly population, the function of the organs of the elderly is declining, the disease is increasing, the disability rate of the elderly and the nursing work are signif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/752A61K9/10A61K9/08A61K9/16A61K9/20A61K9/48A61P3/06A61P9/10
Inventor 颜德馨贺敏
Owner CHONGQING TAIJI INDAL GROUP